Digital twins enable faster recruitment with higher powered, individualized trials [capable of generating] additional data from the same or fewer number of patients.
Opinion: Poorly constructed AI algorithms for drug discovery and testing have the potential to cause harm. The FDA should play an important role in ensuring that AI-based drug development tools meet appropriate standards.
How Companies Are Populating External Control Arms To Speed Clinical Trial Enrollment
Researchers at Unlearn.AI, a startup that designs software tools for clinical research, think that artificial intelligence has a valuable role to play in personalizing diagnosis and treatment.